370 results on '"Humblet Y"'
Search Results
2. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma
3. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
4. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer
5. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
6. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
7. Effect of hospital volume on quality of care and outcome after rectal cancer surgery
8. Population Pharmacokinetics Analysis of Regorafenib and its active Metabolites from the Phase III CORRECT study of metastatic colorectal cancer: ID 006
9. Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project
10. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
11. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients
12. SINUSOIDAL OBSTRUCTION SYNDROME RELATED TO CHEMOTHERAPY FOR COLORECTAL LIVER METASTASES: PREDICTIVE FACTORS OF HIGH GRADE LESIONS AND PROTECTIVE EFFECT OF BEVACIZUMAB: BF051
13. Clearance kinetics of CD34+ cells from peripheral blood: an independent predictor of hematologic recovery after high-dose chemotherapy and hematopoietic stem cell transplantation
14. Panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC): results from the randomised phase III PRIME study: PO349
15. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study
16. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
17. Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer
18. A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: 3552
19. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results: 3512
20. Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
21. Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC)
22. Result of two randomized trials comparing nolatrexed (Thymitaq™) versus methotrexate in patients with recurrent head and neck cancer
23. Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine*
24. Phase II study of vinorelbine in patients with androgen-independent prostate cancer
25. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma
26. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
27. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer
28. Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
29. Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: Prolonged intrathoracic tumor control and high central nervous system relapse rate
30. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
31. PET, CT and tumor markers in the evaluation of postchemotherapy residuals in metastatic germ-cell tumors
32. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
33. Characterization of the immunoscore of synchronous resected primary tumor and liver colorectal cancer metastases
34. Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial
35. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)
36. Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centre
37. 1804P - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
38. New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report
39. Phase 3 correct trial of regorafenib in metastatic colorectal cancer (MCRC)
40. La Resistance A La Chimiotherapie: Progres Recents
41. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
42. Cavitation of lung metastases induced by regorafenib is associated with radiological response in metastatic colorectal cancer: data from the phase III correct study
43. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months
44. 2015 Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study
45. 2154 Metastatic colorectal cancer has heterogeneous immune microenvironment and mutational expression
46. Subgruppenanalyse von Patienten mit metasiertem kolorektalen Karzinom (mKRK), die unter Regorafenib (REG) in der CORRECT-Studie ein progressionsfreies Überleben von mehr als 4 Monaten hatten
47. Tien jaar onderzoek naar de bedreigde rivierdonderpad (**Cottus perifretum*) in Vlaanderen, met bijzondere aandacht voor de Laarse Beek
48. A phase I study of vinblastine tryptophan ester
49. Final Results of a Randomized Phase Ii Study with Neo-Adjuvant Triplet or Doublet Therapy, Radiation and Total Mesorectal Excision for Locally Advanced Rectal Cancer: Axe Beam
50. B Cells (Cd20+) Associated to Tumor Infiltrating Cytotoxic T-Cells Observed on Resected Liver Colorectal Metastases (Lcm) are Prognostic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.